🌍·8h agodiscoveryTier 3 · Aggregated media
Enterprise value to EBITDA forward of Hunan Er-Kang Pharmaceutical Co., Ltd. Class A – SZSE:300267
Publisher
t
tradingview.com
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the attributed publisher through Google News.
Open via Google NewsAt a glance
- Publisher
- tradingview.com
- Region
- Global
- Scope
- discovery
- Published
- September 27, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
This record currently routes through Google News. Confirm important claims against the publisher or a primary record.
Source: tradingview.com
Scope: discovery
Evidence: Tier 3 · Aggregated media
Related coverage
More related coverage
The Whistler Newspaper/3h ago
High Costs,Taxes Keep Nigeria Dependent On Imported Drug Inputs—PSN
Investing.com India/5h ago
Form 144 Legend Biotech Corp For: 27 September By Investing.com
simplywall.st/5h ago
3 Indian Growth Stocks With Revenue Growth Up To 27%
ETV Bharat/6h ago